Alpha-particles for targeted therapySGOUROS, George.Advanced drug delivery reviews. 2008, Vol 60, Num 12, pp 1402-1406, issn 0169-409X, 5 p.Article

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphismsLIU, Sariah; KURZROCK, Razelle.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 883-891, issn 0305-7372, 9 p.Article

Ciblage thérapeutique personnalisé par analyse d'exomes = Personalized therapeutic targeting by exome analysisLAMY, Aude; ANGOT, Emilie; SABOURIN, Jean-Christophe et al.Annales de pathologie (Print). 2012, Vol 32, issn 0242-6498, S44-S45, HS1Conference Paper

Epigenetics and OncologyMUMMANENI, Padmaja; SHORD, Stacy S.Pharmacotherapy. 2014, Vol 34, Num 5, pp 495-505, issn 0277-0008, 11 p.Article

Immunseneszenz: Bestandsaufnahme und molekulare Grundlagen : Hautalterung/Anti-Aging-Strategien = Immunosenescence. Current status and molecular mechanisms : Skin Aging/Anti-aging StrategiesPETERS, T.Der Hautarzt. 2011, Vol 62, Num 8, pp 598-606, issn 0017-8470, 9 p.Article

Novel agents in the era of targeted therapy : what have we learned and how has our practice changed?BASELGA, J.Annals of oncology. 2008, Vol 19, issn 0923-7534, vii281-vii288, SUP7Article

Future prospects for oncolytic therapyMCCORMICK, Frank.Oncogene (Basingstoke). 2005, Vol 24, Num 52, pp 7817-7819, issn 0950-9232, 3 p.Article

Contemporary pre-clinical development of anticancer agents -What are the optimal preclinical models?DAMIA, Giovanna; D'INCALCI, Maurizio.European journal of cancer (1990). 2009, Vol 45, Num 16, pp 2768-2781, issn 0959-8049, 14 p.Article

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsMIEDERER, Matthias; SCHEINBERG, David A; MCDEVITT, Michael R et al.Advanced drug delivery reviews. 2008, Vol 60, Num 12, pp 1371-1382, issn 0169-409X, 12 p.Article

Regorafenib: carving a niche in the crowded therapeutic landscapeSIROHI, Bhawna; DEEPA SUSAN PHILIP; SHRIKHANDE, Shailesh V et al.Expert review of anticancer therapy. 2013, Vol 13, Num 4, pp 385-393, issn 1473-7140, 9 p.Article

Truncated HER2: implications for HER2-targeted therapeuticZAGOZDZON, Radoslaw; GALLAGHER, William M; CROWN, John et al.Drug discovery today. 2011, Vol 16, Num 17-18, pp 810-816, issn 1359-6446, 7 p.Article

Targeted Delivery of a Photosensitizer to Aggregatibacter actinomycetemcomitans BiofilmSUCI, Peter; KANG, Sebyung; GMÜR, Rudolf et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2489-2496, issn 0066-4804, 8 p.Article

Pharmacokinetic Considerations for New Targeted TherapiesBAKER, S. D; HU, S.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 2, pp 208-211, issn 0009-9236, 4 p.Article

CD74 : A new candidate target for the immunotherapy of B-cell neoplasmsSTEIN, Rhona; MATTES, M. Jules; CARDILLO, Thomas M et al.Clinical cancer research. 2007, Vol 13, Num 18, issn 1078-0432, 5556s-5563s, 2Conference Paper

Discovery of Mesothelin and Exploiting It as a Target for ImmunotherapyPASTAN, Ira; HASSAN, Raffit.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 11, pp 2907-2912, issn 0008-5472, 6 p.Article

CD73: A Novel Target for Cancer ImmunotherapyBIN ZHANG.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 16, pp 6407-6411, issn 0008-5472, 5 p.Article

Lymphangiogenesis factors : a target for therapy?GRIFFIOEN, Arjan W.Blood. 2009, Vol 113, Num 18, pp 4135-4136, issn 0006-4971, 2 p.Article

The necessity of nuclear reactors for targeted radionuclide therapiesKRIJGER, Gerard C; PONSARD, Bernard; HARFENSTELLER, Mark et al.Trends in biotechnology (Regular ed.). 2013, Vol 31, Num 7, pp 390-396, issn 0167-7799, 7 p.Article

Une évaluation ciblée pour les thérapies ciblées : Evaluation de la réponse tumorale = A targeted evaluation for targeted therapies : Evaluation of tumoral responseDROMAIN, Clarisse.Hépato-gastro & oncologie digestive. 2012, Vol 19, Num 3, pp 201-204, issn 2115-3310, 4 p.Article

Mélanome, l'espoir des nouvelles thérapies ciblées : Soleil, mon meilleur ennemiSARASIN, Alam.Biofutur (Puteaux). 2011, Num 323, issn 0294-3506, p. 47Article

Keeping Out the Bad Guys : Gateway to Cellular Target TherapyKITAMURA, Takanori; TAKETO, Makoto M.Cancer research (Baltimore). 2007, Vol 67, Num 21, pp 10099-10102, issn 0008-5472, 4 p.Article

Molecular targeted therapy for neuroendocrine tumorsYAO, James C; HOFF, Paulo M.Hematology/oncology clinics of North America. 2007, Vol 21, Num 3, issn 0889-8588, x, 575-581 [8 p.]Article

Discovery of Inhibitors of 4'-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial TherapyDE JONGE, Boudewijn L. M; WALKUP, Grant K; JOHNSTONE, Michele et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6005-6015, issn 0066-4804, 11 p.Article

Nuclear transport : Target for therapyFAUSTINO, R. S; NELSON, T. J; TERZIC, A et al.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 6, pp 880-886, issn 0009-9236, 7 p.Article

Drug development in pancreatic cancer: Finally, biology begets therapyCOHEN, Steven J; MEROPOL, Neal J.International journal of gastrointestinal cancer. 2003, Vol 32, Num 2-3, pp 91-106, issn 1537-3649, 16 p.Article